CD274 and neoplasm: Blocking PD-L1, which is expressed on the tumor cells of ENKTL and ANKL patients, can restore immune effector function in the tumor microenvironment and may produce a synergistic effect through the augmentation of the immune-mediated anticancer response triggered by Isatixumab.